Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 11;23(1):6.
doi: 10.1186/s12893-022-01892-6.

Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study

Affiliations

Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study

Shinichiro Yamada et al. BMC Surg. .

Abstract

Background: We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A.

Methods: We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADCHigh (n = 72) and ADCLow (n = 30) groups, and compared clinicopathological factors between the two groups.

Results: The ADCLow group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADCHigh group. In overall survival, the ADCLow group showed significantly worse prognosis than the ADCHigh group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor.

Conclusion: ADC values can be used to estimate the prognosis of early HCC.

Keywords: Apparent diffusion coefficient; Hepatocellular carcinoma; Magnetic resonance imaging; Prognostic prediction.

PubMed Disclaimer

Conflict of interest statement

M.S. received research grants from TAIHO PHARMACEUTICAL CO., LTD., TSUMURA & CO. Other authors have no competing interest related to this study.

Figures

Fig. 1
Fig. 1
Calculation of ADC values using SYNAPSE VINCENT. This application automatically calculates mean, minimum, and maximum values within free-form green outlines (manual tracing)
Fig. 2
Fig. 2
ROC analysis to determine appropriate cut-off value for minimum ADC values. Cut-off value was 0.84 × 10− 3mm2/s with area under the curve of 0.62
Fig. 3
Fig. 3
Overall survival rate of ADCLow and ADCHigh groups. The ADCLow group showed significantly worse prognosis than the ADCHigh group (p < 0.01)
Fig. 4
Fig. 4
Disease-free survival rate of ADCLow and ADCHigh groups. There was no significant difference between the two groups
Fig. 5
Fig. 5
Recurrent patterns of ADCLow and ADCHigh groups. The ADCLow group showed significantly higher rates of multiple liver and extra-hepatic recurrence (p < 0.05)
Fig. 6
Fig. 6
Rate of early recurrence within 2 years of surgery. The ADCLow group showed higher rates of early recurrence compared with the ADCHigh group (p < 0.01)

Similar articles

Cited by

References

    1. Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2009;13:233–47. doi: 10.1016/j.cld.2009.02.007. - DOI - PubMed
    1. Clinical practice guidelines for hepatocellular carcinoma. The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. - PubMed
    1. Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: historical evolution of transplantation criteria. World J Clin Cases. 2022;10:10413–27. doi: 10.12998/wjcc.v10.i29.10413. - DOI - PMC - PubMed
    1. European Association For The Study Of The Liver 1; European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43. doi: 10.1016/j.jhep.2011.12.001. - DOI - PubMed
    1. Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection Versus local ablation therapies for Hepatocellular Carcinoma within the Milan Criteria: a systematic review and Meta-analysis. Ann Surg. 2021;273:656–66. doi: 10.1097/SLA.0000000000004350. - DOI - PubMed

MeSH terms